SCHEMBL3713620

SCHEMBL3713620

O=[N+]([O-])c1ccc(Cl)c(N=Cc2c(O)ccc3ccccc23)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RRM1 P23921 4/20 0.57
▸ KMT2A Q03164 12/20 0.54
▸ MEN1 O00255 10/20 0.54
▸ GAA P10253 5/20 0.54
▸ MAPT P10636 4/20 0.54
▸ KDM4E B2RXH2 4/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ ATM Q13315 1/20 0.54
▸ IDO1 P14902 2/20 0.52
▸ POLB P06746 5/20 0.51
▸ PSMD14 O00487 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ THRB P10828 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ CASP6 P55212 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9313016 0.78 CA12 (0.54) KMT2AMEN1GAAMAPTKDM4E
SCHEMBL9313011 0.78 CA12 (0.54) KMT2AMEN1GAAMAPTKDM4E
SCHEMBL13479598 0.78 RRM1 (0.64) RRM1KMT2AMEN1GAAMAPT
SCHEMBL15347364 0.78 RRM1 (0.64) RRM1KMT2AMEN1GAAMAPT
SCHEMBL23761140 0.77 KMT2A (0.87) RRM1KMT2AMEN1GAAMAPT
SCHEMBL13840419 0.74 KMT2A (0.71) RRM1KMT2AMEN1GAAMAPT
SCHEMBL22624834 0.74 MAPT (0.70) KMT2AMEN1GAAMAPTKDM4E
SCHEMBL17395842 0.73 MAPT (0.65) KMT2AMEN1GAAMAPTKDM4E
SCHEMBL17395843 0.73 MAPT (0.65) KMT2AMEN1GAAMAPTKDM4E
SCHEMBL18963233 0.73 RRM1 (0.71) RRM1KMT2AMEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791299-B2 Compounds for the inhibition of herpes viruses UNIVERSITE LAVAL (CA) 2014-07-29 — — US claimed
US-20120157538-A1 Compounds for the Inhibition of Herpes Viruses UNIVERSITE LAVAL (CA) 2012-06-21 — — US claimed
US-8791299-B2 Compounds for the inhibition of herpes viruses UNIVERSITE LAVAL (CA) 2014-07-29 — — US disclosed
US-20120157538-A1 Compounds for the Inhibition of Herpes Viruses UNIVERSITE LAVAL (CA) 2012-06-21 — — US disclosed
WO-2010132992-A1 COMPOUNDS FOR THE INHIBITION OF HERPESVIRUSES UNIVERSITé LAVAL (CA) 2010-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157538-A1 Compounds for the Inhibition of Herpes Viruses NOS3, NOS1, DNA2 RRM1 2179/4885KMT2A 523/4885MEN1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback